CLINUVEL – update on EPP treatment in England

Following publication of the findings of the latest appeal against England’s National Institute for Health and Care Excellence (NICE), CLINUVEL’s Director of Global Operations, Mr Lachlan Hay, addresses erythropoietic protoporphyria (EPP) patients to provide an update on EPP patient treatment in England and the Company’s next steps.

Read the announcement that was released earlier today..

Related Articles

Get in Touch


Latest Posts